hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06264492 id: 55777205 briefTitle: Delving Into Participation Trends of Scleroderma Clinical Trials overallStatus: NOT_YET_RECRUITING date: 2025-03 date: 2026-03 date: 2027-03 date: 2024-02-20 date: 2024-02-28 name: Power Life Sciences Inc. class: INDUSTRY briefSummary: Typically, specific demographic subsets tend to exhibit greater engagement in medical research. Nonetheless, there is insufficient research elucidating the trial characteristics influencing the participation of these particular demographics.
The study will analyze data from diverse demographic viewpoints to uncover recurring trends that could provide valuable insights for future patients with scleroderma. conditions: Scleroderma studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 500 type: ESTIMATED measure: Rate of patients in clinical research for scleroderma measure: Number of scleroderma study participants who stay committed until clinical study wraps up sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Power Life Sciences city: San Francisco state: California zip: 94107 country: United States name: Michael B Gill role: CONTACT phone: 415-900-4227 email: https://www.withpower.com/contact-us@withpower.com lat: 37.77493 lon: -122.41942 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-02-09 uploadDate: 2024-02-09T10:51 filename: ICF_000.pdf size: 71611 hasResults: False
nctId: NCT06264479 id: PEAR-TREE2 briefTitle: Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2 acronym: PEAR-TREE2 overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-09-30 date: 2029-03-31 date: 2024-02-20 date: 2024-04-02 name: Ourotech, Inc. class: INDUSTRY name: Royal Free Hospital NHS Foundation Trust name: Cambridge University Hospitals NHS Trust name: East & North Herts NHS Trust name: Imperial College Healthcare NHS Trust briefSummary: Pear Bio has developed a predictive biomarker technology that combines 3D cell culture, microscopy and computer vision to measure the response of an individual patient's tumor sample to different systemic therapy regimens that are tested simultaneously ex vivo.
The oncologist will be blinded to the response on the Pear Bio test (the test will be run in parallel with the patient's treatment). The primary objective of this study is to establish the sensitivity and specificity of Pear Bio's test results against patient outcomes (objective response, progression-free survival, depth and duration of response, overall survival). conditions: Kidney Cancer conditions: Renal Cell Cancer Metastatic studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Biopsy measure: Objective Response Rate correlation accuracy (sensitivity & specificity) measure: Complete Response rate correlation accuracy (sensitivity & specificity) measure: Deep Response rate correlation accuracy (sensitivity & specificity) measure: Durable Response rate correlation accuracy (sensitivity & specificity) measure: PFS prediction accuracy measure: Culture success rate measure: Hazard ratio by biomarker group measure: OS prediction accuracy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Addenbrooke's Hospital city: Cambridge state: Cambridgeshire zip: CB2 0QQ country: United Kingdom name: Kate Fife role: CONTACT lat: 52.2 lon: 0.11667 facility: Mount Vernon Cancer Centre city: London zip: HA6 2RN country: United Kingdom name: Anand Sharma role: CONTACT lat: 51.50853 lon: -0.12574 facility: Imperial College Healthcare NHS Trust city: London zip: W6 8RF country: United Kingdom lat: 51.50853 lon: -0.12574 facility: Royal Free NHS Foundation Trust city: London country: United Kingdom name: Ekaterini Boleti, MD PhD MRCP role: CONTACT phone: 020 7830 2396 phoneExt: 34476 lat: 51.50853 lon: -0.12574 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-07-28 uploadDate: 2023-07-28T07:18 filename: Prot_SAP_000.pdf size: 424039 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-07-28 uploadDate: 2023-07-28T07:19 filename: ICF_001.pdf size: 197013 hasResults: False
nctId: NCT06264466 id: IECED-010112023 briefTitle: Safety and Efficacy of a Novel Flexible Bipolar in POEM overallStatus: RECRUITING date: 2023-12-01 date: 2024-12-01 date: 2025-01-15 date: 2024-02-20 date: 2024-02-20 name: Instituto Ecuatoriano de Enfermedades Digestivas class: OTHER briefSummary: Per-oral endoscopic myotomy (POEM) is a minimally invasive therapy for achalasia. The procedure has demonstrated high technical and clinical success with lower adverse events. Different types of knives have been used for cutting and coagulation during the procedure; however, exchanging accessories is sometimes needed to perform all the stages of POEM.
This single-center, prospective, interventional study will include patients with achalasia submitted to POEM procedure, with or without fundoplication (POEM-F). All stages (mucosal incision, submucosal tunneling, myotomy) of POEM will be performed using the Speedboat ultraslim flexible catheter. Technical and clinical success, along with safety will be the primary endpoints; while, post-procedure reflux symptoms and quality of life will be assessed as secondary outcomes with reflux severity index (RSI) and the Northwestern Esophageal Quality of Life (NEQOL), respectively. conditions: Esophageal Achalasia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: interventional trial primaryPurpose: TREATMENT masking: NONE count: 73 type: ESTIMATED name: POEM with Speedboat Ultraslim measure: Technical success of procedure measure: Clinical success of procedure measure: Frequency of adverse events attributable to the procedure measure: Rate of Gastroesophageal reflux disease measure: Assessment of Gastroesophageal reflux disease severity measure: Change in health-related quality of life after POEM sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Instituto Ecuatoriano de Enfermedades Digestivas (IECED) status: RECRUITING city: Guayaquil state: Guayas zip: 090505 country: Ecuador name: Carlos Robles-Medranda, MD FASGE role: CONTACT phone: +593989158865 email: carlosoakm@yahoo.es role: CONTACT email: carlosoakm@yahoo.es name: Carlos Robles-Medranda, MD role: PRINCIPAL_INVESTIGATOR name: Michel Kahaleh, MD role: SUB_INVESTIGATOR name: Eduardo Albeniz, MD role: SUB_INVESTIGATOR name: Juan Alcivar-Vasquez, MD role: SUB_INVESTIGATOR name: Maria Egas-Izquierdo, MD role: SUB_INVESTIGATOR name: Jorge Baquerizo-Burgos, MD role: SUB_INVESTIGATOR name: Domenica Cunto, MD role: SUB_INVESTIGATOR name: Miguel Puga-Tejada, MD role: SUB_INVESTIGATOR name: Martha Arevalo-Mora, MD role: SUB_INVESTIGATOR name: Raquel Del Valle, MD role: SUB_INVESTIGATOR name: Hannah Pitanga-Lukashok, MD role: SUB_INVESTIGATOR lat: -2.20584 lon: -79.90795 hasResults: False
nctId: NCT06264453 id: KH-001-D201 briefTitle: A Study to Evaluate the Efficacy and Safety of KH001 in Patients With Dentin Hypersensitivity overallStatus: NOT_YET_RECRUITING date: 2024-03-11 date: 2024-08-23 date: 2024-08-30 date: 2024-02-20 date: 2024-02-21 name: HysensBio Co., Ltd class: INDUSTRY briefSummary: The purpose of this study is to evaluate the efficacy and safety of KH001 in patients with dentin hypersensitivity. conditions: Dentin Hypersensitivity studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 171 type: ESTIMATED name: KH001 name: Placebo measure: Change from baseline in Schiff sensitivity score measure: Change from baseline in a Schiff sensitivity score measure: Change from baseline in a Tactile threshold measure: Change from baseline in Visual Analogue Scale sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06264440 id: 283HV104 briefTitle: A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-12 date: 2024-05-07 date: 2024-05-07 date: 2024-02-20 date: 2024-03-25 name: Biogen class: INDUSTRY briefSummary: The primary objective of the study is to evaluate the effects of a proton pump inhibitor (PPI) \[rabeprazole\] on BIIB122 pharmacokinetics (PK) after a single dose in healthy participants. The secondary objective of the study is to evaluate the safety and tolerability of BIIB122, with and without a PPI (rabeprazole), after a single dose in healthy participants. conditions: Healthy Volunteer studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 18 type: ACTUAL name: BIIB122 name: Rabeprazole measure: Maximum Observed Concentration (Cmax) of BIIB122 measure: Area Under the Concentration-Time Curve From Time Zero to Time of the Last Measurable Concentration (AUClast) of BIIB122 measure: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of BIIB122 measure: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) sex: ALL minimumAge: 30 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: PPD Development, LP city: Austin state: Texas zip: 78744 country: United States lat: 30.26715 lon: -97.74306 hasResults: False
nctId: NCT06264427 id: KVUG - 2022 - 10 briefTitle: Phenotypic and Genotypic Characterization of Patients With Dysmetabolism in Greenland overallStatus: RECRUITING date: 2022-07-15 date: 2025-12-31 date: 2026-12-31 date: 2024-02-20 date: 2024-02-20 name: Steno Diabetes Center Greenland class: OTHER name: Zealand University Hospital name: University of Copenhagen briefSummary: The goal of this clinical trial is to perform a detailed description of the feno- and genotype of people living with type 2 diabetes and severe obesity who are linked to care at Steno Diabetes Center Greenland.
* Blood samples for full genome sequencing conditions: Diabetes Mellitus, Type 2 conditions: Obesity, Morbid conditions: Obstructive Sleep Apnea conditions: MODY conditions: Diabetic Retinopathy conditions: Diabetic Neuropathies studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Participants will be examined with whole genom sequencing, and diabetes treatment will be accommodated their diabetic fenotype.
'For the intervention, participants will be screened for obstructive sleep apnea (OSA). Participants with signs of OSA will be offered treatment with Continuos Positive Airway Pressure. primaryPurpose: TREATMENT masking: NONE count: 1000 type: ESTIMATED name: Whole genome sequencing name: VAGUS name: NightOwl name: CPAP measure: Number of participants with MODY diabetes and their complication status measure: Number of participants with diabetic complication measure: Number of participants with obstructive sleep apnea measure: CPAP compliance in Greenlandic patients measure: CPAP treatment effect on quality of life measured with the World Health Organization Well-being Index (WHO-5). measure: CPAP treatment effect on daytime sleepiness measured with the functional outcome of sleep questionnaire (FOSQ-10). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Steno Diabetes Center Greenland, Queen Ingrids Hospital status: RECRUITING city: Nuuk state: Sermersooq zip: 3900 country: Greenland name: Mads Mose Jensen, MD. role: CONTACT phone: +299 34 46 23 email: MMSN@peqqik.gl name: Marit Eika Jørgensen, Md. Ph.d role: CONTACT phone: 34 43 24 email: MAEJ@peqqik.gl lat: 64.18347 lon: -51.72157 hasResults: False
nctId: NCT06264414 id: DTT106-III-0123 briefTitle: Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia acronym: AUSTRÁLIA overallStatus: NOT_YET_RECRUITING date: 2025-02 date: 2026-06 date: 2027-07 date: 2024-02-20 date: 2024-02-20 name: EMS class: INDUSTRY briefSummary: The purpose of this study is to assess the safety and efficacy of the DTT106 in the treatment of erectile dysfunction associated with benign prostatic hyperplasia conditions: Prostatic Hyperplasia, Benign conditions: Erectile Dysfunction studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 262 type: ESTIMATED name: DTT106 name: Dutasteride-Tamsulosin measure: Change in the Erectile Function domain score of the International Index of Erectile Function (IIEF-EF) at the end of treatment, from baseline. measure: Change in maximum urinary flow rate (Qmax) measure: Decrease in post-void residual volume (PVR) measure: Improvement in urinary symptoms. measure: Improvement in urinary emptying symptoms measure: Improvement in urinary storage symptoms. measure: Improvement in the participant's quality of life in relation to their urinary condition measure: Improvement in the participant's sexual function measure: Improvement in the participant's orgasmic function. measure: Effectiveness of the treatment in improving the participant's sexual desire measure: Effectiveness in improving the participant's satisfaction with sexual relations measure: Overall satisfaction of the participant regarding their sex life. sex: MALE minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: EMS city: Hortolândia state: São Paulo country: Brazil lat: -22.85833 lon: -47.22 hasResults: False
nctId: NCT06264401 id: menopausal with osteoporsis briefTitle: Treatment Exercises With Core Stability and Dynamic Resistance Exercise for Postmenopausal Women With Osteoporosis overallStatus: NOT_YET_RECRUITING date: 2024-02-22 date: 2024-12-31 date: 2024-12-31 date: 2024-02-20 date: 2024-02-21 name: Cairo University class: OTHER briefSummary: osteoporosis is a common disease that affect most of postmenopausal women. various treatment procedures are used to avoid future complain among postmenopausal population. conditions: Postmenopausal Osteoporosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: intervention: medication the experimental and control groups received (Alendronate) 70 mg 1 tab every week for 4 months.
treatment exercises the experimental group performed core stability and dynamic resistance exercises, a 45-min lumbar-pelvic/core strength and stability exercise program which include 5 min warming up and 5 min cooling down at the end of the session each exercise was executed for three sets of 15 seconds, which gradually upgraded to three sets of 45-second at the fourth month and 10 sec rest between each set and dynamic resistance exercise performed by each woman for 2 sets for 8-12 repetitions gradually along the study of 90 sec rest between each set for a duration of 60 min including 10 min warming up and 10 min cooling down in form of stretching. primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Alendronate name: treatment exercises measure: Dual-energy x-ray absorptiometry measure: Oswestry Disability Index sex: FEMALE minimumAge: 50 Years maximumAge: 60 Years stdAges: ADULT facility: faculty of physical therapy, Cairo university city: Giza zip: 12662 country: Egypt name: Nermeen Abd El Aziem, phd role: CONTACT phone: 01025016087 email: nermeenshaaban93o@yahoo.com lat: 30.00808 lon: 31.21093 hasResults: False
nctId: NCT06264388 id: 20231234 id: R21CA282543 type: NIH link: https://reporter.nih.gov/quickSearch/R21CA282543 briefTitle: DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma overallStatus: RECRUITING date: 2024-05-01 date: 2034-05-01 date: 2034-05-01 date: 2024-02-20 date: 2024-04-26 name: Ashish Shah class: OTHER name: Denovo Biopharma LLC name: National Cancer Institute (NCI) briefSummary: The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled. conditions: High Grade Glioma conditions: Anaplastic Astrocytoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 33 type: ESTIMATED name: DB107-RRV name: DB107-FC measure: Progression Free Survival measure: Overall Survival measure: Assessment of Tumor Status Measured by Response Assessment in Neuro-oncology (RANO) Criteria measure: Number of Treatment Related Toxicities measure: Durable Response Rate (DRR) measure: Durable Clinical Benefit Rate (DCBR) measure: Duration of Durable Response Rate sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Miami Hospital status: RECRUITING city: Miami state: Florida zip: 33136 country: United States name: Leonela Wright, MSN, RN role: CONTACT phone: 305-243-0864 email: lxw612@med.miami.edu name: Ashish Shah, MD role: CONTACT phone: 305-243-6946 email: ashah@med.miami.edu name: Ashish Shah, MD role: PRINCIPAL_INVESTIGATOR lat: 25.77427 lon: -80.19366 hasResults: False
nctId: NCT06264375 id: E-SPORT briefTitle: Effect of a Specific and General Physical Exercise Intervention on Gaming and E-Sport Performance acronym: E-SPORT overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-19 date: 2024-04-19 date: 2024-09-30 date: 2024-02-20 date: 2024-04-23 name: Universitaet Innsbruck class: OTHER briefSummary: The goal of this randomized control intervention study is to test the effect of i) a specific physical training for e-sport and ii) a general physical training on e-sport performance, compared to iii) not training physically at all.
Researchers will compare Group 1, Group 2 and Groups 3 to see if the different trainings (Group 1 and Group 2) have different effect on e-sport performance and if no training (Group 3) differs in e-sport performance development. conditions: Physical Activity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 8 weeks of intervention, where Group 1 does a specific physical training, Group 2 a general physical training and Group 3 who does not train. primaryPurpose: BASIC_SCIENCE masking: NONE maskingDescription: Data is collected and afterwards anonymized during the pre- and post measurement and during the intervention using a weekly questionnaire (activity level, gaming time) count: 28 type: ACTUAL name: Physical exercise measure: Grip Strength (Out-Game) measure: Reaction Time (Out-Game) measure: Anticipation (Out-Game) measure: Whole Body Fitness measure: Gaming Performance - Accuracy/Speed and Anticipation measure: Well-being after training sex: ALL minimumAge: 10 Years maximumAge: 50 Years stdAges: CHILD stdAges: ADULT facility: Department of Sport Science city: Innsbruck state: Tyrol zip: 6020 country: Austria lat: 47.26266 lon: 11.39454 hasResults: False
nctId: NCT06264362 id: K23AG081547 type: NIH link: https://reporter.nih.gov/quickSearch/K23AG081547 id: 1K23AG081547-01 type: NIH link: https://reporter.nih.gov/quickSearch/1K23AG081547-01 briefTitle: Developing a Nonpharmacological Pain Intervention for Community-dwelling Older Adults With Dementia overallStatus: RECRUITING date: 2023-10-09 date: 2027-05-01 date: 2027-05-01 date: 2024-02-20 date: 2024-04-17 name: Drexel University class: OTHER name: National Institute on Aging (NIA) briefSummary: The purpose of this study is to develop an exercise treatment program for knee osteoarthritis that works well for people with memory problems. This study will include two parts. Participants can choose to participate in either or both parts.
Please contact us for any questions. conditions: Pain, Chronic conditions: Dementia, Mild conditions: Mobility Limitation conditions: Physical Disability conditions: Osteo Arthritis Knee conditions: Mild Cognitive Impairment studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: In Phase 1, 15 dyads and 15 clinicians will be interviewed (a dyad equals one person living with mild to very mild dementia and their care partner) to inform design of the intervention. In Phase 2, 20 people living with mild to very mild dementia will be treated with the new intervention. Their care partners may be involved in treatment. primaryPurpose: TREATMENT masking: NONE count: 85 type: ESTIMATED name: Tailored Physical Activity Program measure: Program parameters measure: Program parameters measure: Feasibility of Intervention Measure measure: Perception of program measure: Numeric Pain Score measure: Zarit Burden Interview-Short Form sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Drexel University status: RECRUITING city: Philadelphia state: Pennsylvania zip: 19104 country: United States name: Annalisa Na, PT, PhD role: CONTACT phone: 267-359-5889 email: an838@drexel.edu name: Ben Senderling, MS role: CONTACT phone: 2679800425 email: bms422@drexel.edu lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06264349 id: 05102023 briefTitle: Women and Maternity: Development of a Nutritional Education Project acronym: MATER overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-05-15 date: 2025-11-30 date: 2024-02-16 date: 2024-02-16 name: University of Pavia class: OTHER briefSummary: The "first 1000 days of life", from conception to 2 years of life, are crucial for promoting the health of both mother and baby. During this period, a woman's diet and lifestyle play a significant role in determining the future health of the child. The perinatal period is an ideal time for regular contact with healthcare providers who can institute an intervention to encourage pregnant women to make nutritional changes to improve their health and that of their babies.
Therefore, an educational program on an appropriate lifestyle during the "first 1000 days" can represent a crucial primary prevention strategy in reducing the risk of developing obesity and non-communicable diseases (NCDs) during childhood and later adulthood. conditions: Pregnancy conditions: Lactation studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Quasi-experimental - controlled, non-randomized pilot study primaryPurpose: PREVENTION masking: NONE count: 100 type: ESTIMATED name: Lifestyle Educational Intervention measure: Gestational weight gain management measure: Nutritional aspects evaluation during pregnancy and lactation measure: Physical activity evaluation during pregnancy and lactation measure: Smoking habits during pregnancy and lactation measure: Maternal attitude towards infant feeding. sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False